Bifendate pills are indicated for the treatment of chronic persistent hepatitis with increased ALT. It is also indicated for ALT elevation that was caused by chemical toxicity and drugs.
Bifendate pills produced by Beijing Union Pharmaceutical Factory were researched and developed by Institute of Materia Medica, Chinese Academy of Medical Sciences. It obtained the third prize of National Invention Award in 1983 and was identified as Independent Innovative Products of Beijing in 2009. Since 2000, Bifendate pills have successively registered and entered the markets in countries including Egypt, Indonesia, Vietnam, Burma, Mongolia, South Korea, and so on.
Bifendate pills have been listed in< National Essential Medicine List (for primary healthcare facilities) (edition 2009)> and type A of <Drug Catalogue for National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (edition 2009)>.